Sondex PLC
29 September 2006
Friday 29th September 2006
Sondex plc
("Sondex" or the "Group")
Acquisition of Ultima Labs Inc
Sondex plc announces the acquisition of Ultima Labs Inc ("Ultima Labs"), a
private Houston based technology development company with a range of IP and
products related to Logging While Drilling ("LWD") and Wireline applications for
the oilfield service industry, for a consideration of up to US$9.225 million
(£4.855 million), including sales related earn-out.
Ultima Labs is a technology development company based in Houston, USA. The
primary product that has been developed and is in the process of being
commercialised is for LWD involving multiple depth resistivity measurements of
the rock formations and their fluid content in order to asses the potential for
oil or gas production. This technology is a complementary, next step,
measurement for the existing LWD tools provided by Sondex drilling division.
Ultima Labs have a Memorandum of Understanding to provide these products, with
an initial order to the value of $4.5 million, to a Chinese company that is also
an existing customer of Sondex.
The management of Ultima, who have extensive experience in technology
development for both wireline and drilling applications will remain with the
business and participate in the integration of the technology and development of
future product lines.
Consideration
The maximum consideration of US$9.225 million (£4.855 million) will be settled
as follows:
1. At completion a payment in cash of US$1.65 million (£0.87
million);
2. On each of the first and second anniversaries of completion
a cash payment of US$1.5 million (£0.79 million);
3. A payment of up to US$2.25 million (£1.18 million)
depending on Ultima Labs achieving certain milestones related to the development
and sales of Ultima's CPR Tool, such amount to be satisfied by the issue of up
to 415,584 ordinary shares in Sondex; and
4. Earn-out payments of up to an aggregate maximum of US$2.325
million (£1.224 million) paid annually in cash over a maximum of five years as a
royalty from sales of specified Ultima products.
Funding for the maximum consideration and projected working capital requirements
has been arranged through an extension to the existing bank facilities with the
Bank of Scotland.
* using an exchange rate of £1: $1.9
Martin Perry, Chief Executive of Sondex, commented:
"This acquisition is an excellent strategic fit with Sondex's drilling division.
Ultima Labs have an innovative highly regarded product range with strong IP
protection as well as an extremely skilled and experienced development team,
they will add to the range of high technology products that we can offer to our
existing and new clients across the world."
For further information, please contact:
Sondex Tel: 01252 862 200
Martin Perry (Chief Executive)
Chris Wilks (Finance Director)
Investec Tel: 020 7597 5000
James Grace / Patrick Robb
College Hill Tel: 020 7457 2020
Nick Elwes / Paddy Blewer
www.sondex.com
For further information about Ultima Labs please visit:
www.ultimalabs.com
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.